Page 1884 - Hematology_ Basic Principles and Practice ( PDFDrive )

1668.e8 Part X Transplantation

322. McCarthy PL, Williams L, Harris-Bacile M, et al: A clinical phase I/II 343. Ayash LJ, Clarke M, Adams P, et al: Clinical protocol. Purging of
study of recombinant human interleukin-1 receptor in glucocorticoid- autologous stem cell sources with bcl-x(s) adenovirus for women
resistant graft-versus-host disease. Transplantation 62:626, 1996. undergoing high-dose chemotherapy for stage IV breast carcinoma.
323. Annino L, Vegna ML, Camera A, et al: Treatment of adult acute Hum Gene Ther 12:2023, 2001.
lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA 344. Reddy P, Johnson K, Uberti JP, et al: Nephrotic syndrome associated
ALL 0288 randomized study. Blood 99:863, 2002. with chronic graft-versus-host disease after allogeneic hematopoietic
324. Antin JH, Lee SJ, Neuberg D, et al: A phase I/II double-blind, placebo- stem cell transplantation. Bone Marrow Transplant 38:351, 2006.
controlled study of recombinant human interleukin-11 for mucositis 345. Akpek EK, Altan-Yaycioglu R, Gottsch JD, et al: Spontaneous corneal
and acute GVHD prevention in allogeneic stem cell transplantation. perforation in a patient with unusual unilateral pellucid marginal
Bone Marrow Transplant 29:373, 2002. degeneration. J Cataract Refract Surg 27:1698, 2001.
325. Altvater B, Landmeier S, Pscherer S, et al: 2B4 (CD244) signaling 346. Shulman HM, Sharma P, Amos D, et al: A coded histologic study of
via chimeric receptors costimulates tumor-antigen specific proliferation hepatic graft-versus-host disease after human bone marrow transplanta-
and in vitro expansion of human T cells. Cancer Immunol Immunother tion. Hepatology 8:463, 1988.
58:1991, 2009. 347. Shulman HM, Sale GE, Lerner KG, et al: Chronic cutaneous graft-
326. Weisdorf D, Haake R, Blazar B, et al: Treatment of moderate/severe versus-host disease in man. Am J Pathol 91:545, 1978.
acute graft-versus-host disease after allogeneic bone marrow transplan- 348. Shlomchik WD, Lee SJ, Couriel D, et al: Transplantation’s greatest
tation: an analysis of clinical risk features and outcome. Blood 75:1024, challenges: advances in chronic graft-versus-host disease. Biol Blood
1990. Marrow Transplant 13:2, 2007.
327. Hockenbery DM, Cruickshank S, Rodell TC, et al: A randomized, 349. Parkman R: Is chronic graft versus host disease an autoimmune disease?
placebo-controlled trial of oral beclomethasone dipropionate as a Curr Opin Immunol 5:800, 1993.
prednisone-sparing therapy for gastrointestinal graft-versus-host disease. 350. Sakoda Y, Hashimoto D, Asakura S, et al: Donor-derived thymic-
Blood 109:4557, 2007. dependent T cells cause chronic graft-versus-host disease. Blood
328. Chang C, Storer BE, Scott BL, et al: Hematopoietic cell transplantation 109:1756, 2007.
in patients with myelodysplastic syndrome or acute myeloid leukemia 351. Holländer GA, Widmer B, Burakoff SJ: Loss of normal thymic reper-
arising from myelodysplastic syndrome: similar outcomes in patients toire selection and persistence of autoreactive T cells in graft vs. host
with de novo disease and disease following prior therapy or antecedent disease. J Immunol 152:1609, 1994.
hematologic disorders. Blood 110:1379, 2007. 352. Teshima T, Reddy P, Liu C, et al: Impaired thymic negative selection
329. Greinix HT, Socie G, Bacigalupo A, et al: Assessing the potential role causes autoimmune graft-versus-host disease. Blood 102:429, 2003.
of photopheresis in hematopoietic stem cell transplant. Bone Marrow 353. Alexander KA, Flynn R, Lineburg KE, et al: CSF-1-dependant donor-
Transplant 38:265, 2006. derived macrophages mediate chronic graft-versus-host disease. J Clin
330. Alousi AM, Weisdorf DJ, Logan BR, et al: Etanercept, mycopheno- Invest 124(10):4266–4280, 2014.
late, denileukin or pentostatin plus corticosteroids for acute graft vs. 354. Ratanatharathorn V, Ayash L, Reynolds C, et al: Treatment of chronic
host disease: a randomized phase II trial from the BMT CTN. Blood graft-versus-host disease with anti-CD20 chimeric monoclonal anti-
114:511, 2009. body. Biol Blood Marrow Transplant 9:505, 2003.
331. Di Stasi A, Tey SK, Dotti G, et al: Inducible apoptosis as a safety switch 355. Cutler C, Antin JH: Chronic graft-versus-host disease. Curr Opin Oncol
for adoptive cell therapy. N Engl J Med 365:1673, 2011. 18:126, 2006.
332. Ely P, Dunitz J, Rogosheske J, et al: Use of a somatostatin analogue, 356. Flynn R, Du J, Veenstra RG, et al: Increased T follicular helper cells
octreotide acetate, in the management of acute gastrointestinal graft- and germinal center B cells are required for cGVHD and bronchiolitis
versus-host disease. Am J Med 90:707, 1991. obliterans. Blood 123(25):3988–3998, 2014.
333. Sullivan KM, Agura E, Anasetti C, et al: Chronic graft-versus-host 357. Dubovsky JA, Flynn R, Du J, et al: Ibrutinib treatment ameliorates
disease and other late complications of bone marrow transplantation. murine chronic graft-versus-host disease. J Clin Invest 124(11):4867–
Semin Hematol 28:250, 1991. 4876, 2014.
334. Akpek G, Ambinder RF, Piantadosi S, et al: Long-term results of blood 358. Flynn R, Allen JL, Luznik L, et al: Targeting Syk-activated B cells
and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol in murine and human chronic graft-versus-host disease. Blood
19:4314, 2001. 125(26):4085–4094, 2015.
335. Flowers ME, Parker PM, Johnston LJ, et al: Comparison of chronic 359. Kitko CL, Levine JE, Storer BE, et al: Plasma CXCL9 elevations cor-
graft-versus-host disease after transplantation of peripheral blood stem relate with chronic GVHD diagnosis. Blood 123(5):786–793, 2014.
cells versus bone marrow in allogeneic recipients: long-term follow-up 360. Lee SJ: New approaches for preventing and treating chronic graft-
of a randomized trial. Blood 100:415, 2002. versus-host disease. Blood 105:4200, 2005.
336. Akpek G, Chinratanalab W, Lee LA, et al: Gastrointestinal involve- 361. Stewart BL, Storer B, Storek J, et al: Duration of immunosuppressive
ment in chronic graft-versus-host disease: a clinicopathologic study. Biol treatment for chronic graft-versus-host disease. Blood 104:3501, 2004.
Blood Marrow Transplant 9:46, 2003. 362. Burroughs L, Mielcarek M, Leisenring W, et al: Extending postgrafting
337. Ghayur T, Seemayer T, Lapp WS: Histologic correlates of immune cyclosporine decreases the risk of severe graft-versus-host disease after
functional deficits in graft-vs-host disease. In Burakoff SJ, Deeg HJ, nonmyeloablative hematopoietic cell transplantation. Transplantation
Ferrara J, et al, editors: Graft-vs.-host disease: immunology, pathophysiol- 81:818, 2006.
ogy, and treatment, New York, 1990, Marcel Dekker, p 109. 363. Couriel D, Carpenter PA, Cutler C, et al: Ancillary therapy and sup-
338. Arai S, Vogelsang GB: Management of graft-versus-host disease. Blood portive care of chronic graft-versus-host disease: national institutes of
Rev 14:190, 2000. health consensus development project on criteria for clinical trials in
339. Wingard JR, Piantadosi S, Vogelsgang GB, et al: Predictors of death chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive
from chronic graft-versus-host disease after bone marrow transplanta- Care Working Group Report. Biol Blood Marrow Transplant 12:375,
tion. Blood 74:1428, 1989. 2006.
340. Wingard JR, Vogelsang GB, Deeg HJ: Stem cell transplantation: sup- 364. Lee SJ, Klein JP, Barrett AJ, et al: Severity of chronic graft-versus-host
portive care and long-term complications. Hematology 422:2002. disease: association with treatment-related mortality and relapse. Blood
341. Baker KS, Filipovich AH, Gross TG, et al: Unrelated donor hematopoi- 100:406, 2002.
etic cell transplantation for hemophagocytic lymphohistiocytosis. Bone 365. Socie G, Schmoor C, Bethge WA, et al: Chronic graft-versus-host
Marrow Transplant 42:175, 2008. disease: long-term results from a randomized trial on graft-versus-host
342. Martin PJ, Weisdorf D, Przepiorka D, et al: National Institutes of disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
Health Consensus Development Project on Criteria for Clinical Trials Blood 117(23):6375–6382, 2011.
in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials 366. Sullivan KM, Witherspoon RP, Storb R, et al: Prednisone and azathio-
Working Group report. Biol Blood Marrow Transplant 12:491, 2006. prine compared with prednisone and placebo for treatment of chronic